Dibenzepin


Concise Prescribing Info
Indications/Uses
Depression.
Dosage/Direction for Use
Adult: PO 240-480 mg/day. Up to 720 mg/day in severe depression.
Contraindications
Recent MI, arrhythmias, severe liver disease, manic phase.
Special Precautions
CV disease, history of epilepsy, hepatic impairment, hyperthyroidism, pheochromocytoma, history of mania, psychoses, urinary retention, close-angle glaucoma, concurrent electroconvulsive therapy, diabetes. Pregnancy and lactation, elderly, childn. Porphyria. Avoid abrupt withdrawal. May impair ability to drive.
Drug Interactions
Effects may be enhanced by concomitant use of cimetidine, diltiazem, disulfiram, methylphenidate, ritonavir and verapamil and reduced when used with carbamazepine, rifampicin and oestrogens. Side-effects may be increased by adrenaline, amiodarone, general anaesthetics, SSRIs, anithistamines, antimuscarinics, antipsychotics, anxiolytics and hypnotics, disopyramide, diuretics, flecainide, MAOIs, moclobemide, moxifloxacin, nefopam, nicorandil, noradrenaline, pimozide, procainamide, propafenone, quinidine, selegiline, sibutramine, sotalol, terfenadine, thioridazine and tramadol. Effects of adrenergic neuron blocker, clonidine, barbiturates, nitrates, and primidone are reduced while effects of baclofen, opioid analgesics and thyroid hormones are enhanced.
CIMS Class
ATC Classification
N06AA08 - dibenzepin ; Belongs to the class of non-selective monoamine reuptake inhibitors. Used in the management of depression.
Disclaimer: This information is independently developed by CIMS based on dibenzepin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in